Señales en vivo de 226950.KQ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 02:30):

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases...

Stats
Volumen de hoy	43 715.00
Volumen promedio	108 209
Capitalización de mercado	251.53B
EPS	KRW0 ( 2024-03-15 )
Próxima fecha de ganancias	( KRW0 ) 2024-05-09
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW23.20 (0.15%)

Volumen Correlación

Largo: -0.14 (neutral)

Corto: -0.02 (neutral)

Signal:(44.97) Neutral

OliX Pharmaceuticals,Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OliX Pharmaceuticals,Inc Correlación - Moneda/Commodity

0.44
( neutral )

0.23
( neutral )

0.44
( neutral )

0.45
( neutral )

0.13
( neutral )

0.06
( neutral )

OliX Pharmaceuticals,Inc Finanzas

Annual	2023
Ingresos:	KRW17.06B
Beneficio Bruto:	KRW14.42B (84.52 %)
EPS:	KRW-1 323.81

FY	2023
Ingresos:	KRW17.06B
Beneficio Bruto:	KRW14.42B (84.52 %)
EPS:	KRW-1 323.81

FY	2022
Ingresos:	KRW9.32B
Beneficio Bruto:	KRW7.35B (78.83 %)
EPS:	KRW-1 422.69

Financial Reports:

No articles found.

OliX Pharmaceuticals,Inc

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.